Arctic Bioscience - Mandatory notification of trade

15 Oct 2024 15:53 CEST

Gold Coast Nutrition, a legal person closely associated with a person
discharging managerial responsibility in Arctic Bioscience, has today bought
5,000 shares in Arctic Bioscience at an average price of NOK 3,08 per share.
Following the transaction, Gold Coast Nutrition holds 455,000 shares in Arctic
Bioscience.

CSO at Arctic Bioscience, Hogne Hallaråker, is the owner of Gold Coast
Nutrition.

Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
§ 5-12.

For more information, please contact:

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site

629675_20241015_Appendix_3_Notifying_Transactions_Gold_Coast_Nutrition.pdf